Dxcover has acquired the intellectual property for its liquid biopsy technology and multi cancer early detection (MCED) platform in a deal with the University of Strathclyde.
The Glasgow-based company's technology has moved the early detection of brain cancer one step closer, following recent breakthroughs.
The deal means that Dxcover now owns all of the patents for its technology platform and has no requirement to pay royalties.
Published in the peer-reviewed Cancers academic journal, the health-tech firm has shown that its liquid biopsy technique is effective even in the earlier days of cancer growth, at a smaller volume and lower stage.
The study involved 177 patients with varying sizes of brain tumours providing blood samples for analysis by Dxcover. Samples underwent the spectroscopic analysis under infra-red light and were then processed using machine learning software.
Earlier detection of brain cancer, when a tumour is smaller, reduces the harm from surgery and other treatments.
Dr Matt Baker, chief technical officer and co-founder at Dxcover, said: “The study demonstrates the effectiveness of our Dxcover Brain Cancer Liquid Biopsy at detecting even the smallest brain tumours, which is great news for the care of future brain cancer patients, increasing treatment options and potentially extending life expectancy.”
Don't miss the latest headlines with our twice-daily newsletter - sign up here for free.
